Thursday, 22 Jun 2017

You are here

Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women

It is estimated that 50% of women over the age of 50 will experience a facture related to osteoporosis. And while there are many effective therapies to lower this risk, the optimal duration of treatment is the subject of current debate.

The Journal of the American Geriatric Society has reported that older women receiving bisphosphonate therapy for greater than 10-13 years were more likely to suffer from fractures. ( Citation source: http://buff.ly/2qL1yQK)

In a subset observational study from the Womens Health Initiative, 5,120 older women who received bisphosphonates for greater than 2 years were assessed at different time intervals based on years of bisphosphonate use (2 years, 3–5, 6–9, 10–13 years). Fracture risk was calculated using 2 years as the referent group.

The length of time on bisphosphonates varied, with 13% takng bisphosphonates for 2 years,  34% for 3-5 years, 20% for 6-9 years, and 33% for 10-13 years.

The aveage age was 80 years and there were a total of 1313 fractures:127 hip, 159 wrist/forearm, and 235 vertebral fractures.

With 10-to-13 years of bisphosphonate use a 29% higher risk of any and all fractures was seen compared to 2 years of use (HR = 1.29, 95%CI; 1.07–1.57).  However, this was not statistically significant for hip (HR = 1.66, 95% CI = 0.81–3.40), clinical vertebral (HR = 1.65, 95% CI = 0.99–2.76), or wrist fracture (HR = 1.16, 95% CI = 0.67–2.00).

In older women at high risk of fracture, it appears that prolonged use (10-to-13 years) of bisphosphonate use was associated with higher risk of any clinical fracture compared to shorter periods (2 years) of use.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Bone Turnover Markers in Practice: A Guide for the Rheumatologist

Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.

However there have been difficulties with poor between-lab reproductivity, insufficiently controlled heterogeneity, and pre-analytical variability of the assays; making BTMs vastly unpopular amongst practicing rheumatologists.

2017 ACR Guideline on Glucocorticoid-Induced Osteoporosis

The American College of Rheumatology has updated its 2010 guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. The guideline provides recommendations on assessing fracture risk and treatment for adults and special patient populations, including women of childbearing potential, adults treated with very high-dose glucocorticoids, adults with organ transplants, and children ages 4-17.

Chondroitin Effective in Knee OA. Or is it?

Reginster and colleagues have reported on the results of the CONCEPT trial showing that osteoarthritis (OA) patients treated 800 mg/day of  pharmaceutical-grade chondroitin sulfate (CS) have less VAS pain scores and improved function over 6 months therapy. These results were superior to placebo and equivalent to celecoxib in reducing in symptomatic OA knee pain.

High Fiber Intake May Decrease Osteoarthritis Knee Pain

 

Dai, Felson and colleagues report in Annals of Rheumatic Disease that high dietary fiber lowers the risk of symptomatic osteoathritis (SxOA), but the radiographic benefits remain unclear. (Citation source http://buff.ly/2rHv9yd)

Anti-Sclerostin Drug Hampered by Heart Problems

Reuters reports that FDA approval of romosozumab (brand name Evenity) may be held up because of higher rates of cardiac events seen in a late-stage clinical trial.